Search

Your search keyword '"L'hermite, E"' showing total 4 results
Start Over Author "L'hermite, E"
4 results on '"L'hermite, E"'

1. The VIZIER project: Preparedness against pathogenic RNA viruses

Author

Coutard, B., Gorbalenya, A.E., Snijder, E.J., Leontovich, A.M., Poupon, A., De Lamballerie, X., Charrel, R., Gould, E.A., Gunther, S., Norder, H., Klempa, B., Bourhy, H., Rohayem, J., L’hermite, E., Nordlund, P., Stuart, D.I., Owens, R.J., Grimes, J.M., Tucker, P.A., Bolognesi, M., Mattevi, A., Coll, M., Jones, T.A., Åqvist, J., Unge, T., Hilgenfeld, R., Bricogne, G., Neyts, J., La Colla, P., Puerstinger, G., Gonzalez, J.P., Leroy, E., Cambillau, C., Romette, J.L., and Canard, B.

Published
2008
Full Text
View/download PDF

2. The VIZIER project: Preparedness against pathogenic RNA viruses

Author

Coutard, B, Gorbalenya, AE, Snijder, EJ, Leontovich, AM, Poupon, A, De Lamballerie, X, Charrel, R, Gould, EA, Gunther, S, Norder, H, Klempa, B, Bourhy, H, Rohayem, J, L'hermite, E, Nordlund, P, Stuart, DI, Owens, RJ, Grimes, JM, Tucker, PA, and Bolognesi, M

Subjects
PROTEIN EXPRESSION, ESCHERICHIA-COLI, CRYSTAL-STRUCTURE, CATALYTIC DOMAIN, DENGUE VIRUS
Abstract

Life-threatening RNA viruses emerge regularly, and often in an unpredictable manner. Yet, the very few drugs available against known RNA viruses have sometimes required decades of research for development. Can we generate preparedness for outbreaks of the, as yet, unknown viruses? The VIZIER (VIral enZymes InvolvEd in Replication) (http://www.vizier-europe.org/) project has been set-up to develop the scientific foundations for countering this challenge to society. VIZIER studies the most conserved viral enzymes (that of the replication machinery, or replicases) that constitute attractive targets for drug-design. The aim of VIZIER is to determine as many replicase crystal structures as possible from a carefully selected list of viruses in order to comprehensively cover the diversity of the RNA virus universe, and generate critical knowledge that could be efficiently utilized to jump-start research on any emerging RNA virus. VIZIER is a multidisciplinary project involving (i) bioinformatics to define functional domains, (ii) viral genomics to increase the number of characterized viral genomes and prepare defined targets, (iii) proteomics to express, purify, and characterize targets, (iv) structural biology to solve their crystal structures, and (v) pre-lead discovery to propose active scaffolds of antiviral molecules. (C) 2007 Elsevier B.V. All rights reserved.

Published
2008

4. Efficacy and Tolerance of Vascular Electrical Stimulation Therapy in the Management of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Phase II Single-Centre Randomized Study in Ivory Coast.

Author

Botti RP, Bokoum SS, L'Hermite E, Silue DA, Kouakou B, Bognini SA, Agoua SA, Mandeng Ma Linwa E, Ayemou R, and Koffi KG

Abstract

Background: Vaso-occlusive crisis (VOC) is the primary cause of hospitalization in patients with sickle cell disease. Treatment mainly consists of intravenous morphine or nonsteroidal anti-inflammatory drugs (NSAIDs), which have many dose-related side effects. The question arises as to whether vascular electrical stimulation therapy (VEST) could be effective or not on VOCs., Objective: To measure the effectiveness and safety of VEST in reducing the median time spent in severe VOC., Methods: We conducted a phase II, single blinded, randomized, controlled, triple-arm, comparative trial. We included thirty (30) adult patients with severe vaso-occlusive crisis. The study arms were divided as follows: our control group (group 0) constituted of 10 patients followed with conventional therapy (Analgesics + Hydration + NSAIDs), while 20 patients were divided equally into two interventional arms-10 patients followed with VEST + Analgesics + Hydration (group 1) and the other 10 patients followed with VEST + Analgesics + Hydration + NSAIDs (group 2). The primary efficacy endpoint was median time to severe crisis elimination. The secondary end points were median time to end-of-crisis, median tramadol consumption, progress of the haemoglobin level over 3 days, side effects, and treatment failure., Results: The age ranged from 14 to 37 years, including 23 women. We noted a beneficial influence of the VEST on the median time to severe crisis (VAS greater than 2) elimination; 17 hours (group 1) against 3.5 hours (group 2) p =0.0166 and 4 hours (group 3) with p value = 0.0448. Similar significant results were obtained on the diminution of total duration of the crisis (VAS over 0) and median tramadol consumption in patients in the interventional arms., Conclusion: These statistically significant results in the interventional arms suggest that VEST could be an alternative treatment of VOC in sickle cell patients., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2021 Renée-Paule Botti et al.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results